|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIR205HG |
Gene summary for MIR205HG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIR205HG | Gene ID | 642587 |
| Gene name | MIR205 host gene | |
| Gene Alias | LINC00510 | |
| Cytomap | 1q32.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 642587 | MIR205HG | CCI_1 | Human | Cervix | CC | 3.70e-54 | 2.47e+00 | 0.528 |
| 642587 | MIR205HG | CCI_2 | Human | Cervix | CC | 1.23e-38 | 2.66e+00 | 0.5249 |
| 642587 | MIR205HG | CCI_3 | Human | Cervix | CC | 3.58e-76 | 3.51e+00 | 0.516 |
| 642587 | MIR205HG | CCII_1 | Human | Cervix | CC | 2.05e-96 | 2.48e+00 | 0.3249 |
| 642587 | MIR205HG | sample1 | Human | Cervix | CC | 2.12e-71 | 1.76e+00 | 0.0959 |
| 642587 | MIR205HG | sample3 | Human | Cervix | CC | 3.64e-145 | 1.94e+00 | 0.1387 |
| 642587 | MIR205HG | L1 | Human | Cervix | CC | 1.91e-63 | 1.74e+00 | 0.0802 |
| 642587 | MIR205HG | T1 | Human | Cervix | CC | 5.45e-123 | 1.82e+00 | 0.0918 |
| 642587 | MIR205HG | T2 | Human | Cervix | CC | 1.63e-12 | 5.62e-01 | 0.0709 |
| 642587 | MIR205HG | T3 | Human | Cervix | CC | 4.05e-136 | 1.91e+00 | 0.1389 |
| 642587 | MIR205HG | LZE11D | Human | Esophagus | HGIN | 1.26e-02 | -9.90e-01 | -0.005 |
| 642587 | MIR205HG | LZE2D | Human | Esophagus | HGIN | 1.17e-08 | 1.88e+00 | 0.0642 |
| 642587 | MIR205HG | LZE2T | Human | Esophagus | ESCC | 1.57e-20 | 2.87e+00 | 0.082 |
| 642587 | MIR205HG | LZE3D | Human | Esophagus | HGIN | 2.09e-20 | 3.01e+00 | 0.0668 |
| 642587 | MIR205HG | LZE4T | Human | Esophagus | ESCC | 2.57e-09 | 9.49e-01 | 0.0811 |
| 642587 | MIR205HG | LZE5T | Human | Esophagus | ESCC | 3.46e-06 | 4.39e-01 | 0.0514 |
| 642587 | MIR205HG | LZE7T | Human | Esophagus | ESCC | 6.41e-21 | 2.59e+00 | 0.0667 |
| 642587 | MIR205HG | LZE8T | Human | Esophagus | ESCC | 2.09e-25 | 1.97e+00 | 0.067 |
| 642587 | MIR205HG | LZE20T | Human | Esophagus | ESCC | 2.08e-19 | 2.29e+00 | 0.0662 |
| 642587 | MIR205HG | LZE21D1 | Human | Esophagus | HGIN | 2.29e-07 | 2.07e+00 | 0.0632 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |